Patients in England and Wales with cardiomyopathy caused by the disorder ATTR amyloidosis will soon be able to access treatment with Alnylam's gene-silencing drug Amvuttra. The ruling by reimbursement ...

Alnylam is riding high today after reporting its RNAi drug vutrisiran showed across-the-board efficacy in cardiomyopathy associated with transthyretin-mediated amyloidosis (ATTR), setting up ...

The outlook for transthyretin amyloidosis (ATTR amyloidosis) depends on factors such as your type, affected organs, and how early you start treatment. Average survival rates differ by type: familial ...

If you’ve been diagnosed with transthyretin cardiac amyloidosis (ATTR-CM), you may be debating between two treatments: transthyretin (TTR) stabilizers and gene silencers. Both drug families are ...

Hereditary ATTR-CM is a genetic condition where mutated TTR genes cause unstable TTR proteins to form amyloid proteins, which can accumulate in the heart and impair its function. If a parent has a TTR ...

The same abnormal proteins that can build up in your heart when you have transthyretin cardiac amyloidosis (ATTR-CM) can also leave deposits in your spine, resulting in spinal stenosis. Spinal ...

The same abnormal proteins that can build up in your heart when you have transthyretin cardiac amyloidosis (ATTR-CM) can also leave deposits in your spine, resulting in spinal stenosis. The symptoms ...

Vutrisiran reduced mortality and cardiovascular events in ATTR-CM patients across all age groups, including those aged 80 and older. The HELIOS-B trial demonstrated consistent benefits in reducing all ...

Researchers at the University of Geneva (UNIGE), in collaboration with the Università della Svizzera Italiana (USI), have succeeded for the first time in determining the three-dimensional structure of ...

The FDA is freeing Intellia Therapeutics' CRISPR therapy from one of two clinical holds, allowing a phase 3 study to resume after a grade 4 liver event and subsequent patient death was reported in the ...

CAMBRIDGE, Mass., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...